Jump to: navigation, search

Chronic myelomonocytic leukemia

1,253 bytes added, 10:43, 24 February 2018
Maintenance after first-line therapy
# Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. [ link to original article] '''contains verified protocol''' [ PubMed]
==Decitabine monotherapy {{#subobject:c9cd47|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|[[#top|back to top]]
===Regimen {{#subobject:fbeb38|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
|[ Santini et al. 2017]
|style="background-color:#91cf61"|Phase II
|style="background-color:#8c96c6"|ORR: 48%
*[[Decitabine (Dacogen)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 5
'''28-day cycles'''
# Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, Cilloni D, Sanna A, Masiera E, Ceccarelli M, Abdel-Wahab O, Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrero D, Saglio G, Figueroa M, Levis A. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018 Feb;32(2):413-418. Epub 2017 Jun 13. [ link to original article] [ link to PMC article] '''contains verified protocol''' [ PubMed]
=Maintenance after first-line therapy=
LookupUsers, editors, emailconfirmed

Navigation menu